Cargando…
Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis
Osteoclasts can interact with osteosarcoma to promote the growth of osteosarcoma. Cisplatin is common in adjuvant chemotherapy of osteosarcoma. However, due to chemoresistance, the efficacy is profoundly limited. Previous studies have found that zoledronic acid (ZA) has osteoclast activation inhibit...
Autores principales: | Liu, Liang, Geng, Huan, Mei, Chengjie, Chen, Liaobin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026287/ https://www.ncbi.nlm.nih.gov/pubmed/33859780 http://dx.doi.org/10.1155/2021/6661534 |
Ejemplares similares
-
SPHK Inhibitors and Zoledronic Acid Suppress Osteoclastogenesis and Wear Particle-Induced Osteolysis
por: Gu, Minghui, et al.
Publicado: (2022) -
Celecoxib enhances anticancer effect of cisplatin and induces anoikis in osteosarcoma via PI3K/Akt pathway
por: Liu, Bing, et al.
Publicado: (2017) -
Effect of Zoledronic Acid on Acro-Osteolysis and Osteoporosis in a Patient with Hajdu-Cheney Syndrome
por: Hwang, Sena, et al.
Publicado: (2011) -
Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration
por: Nooh, Anas, et al.
Publicado: (2017) -
Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway
por: Wei, Xuan, et al.
Publicado: (2021)